Neus · Neutral News Analysis

GSK Shares Fall Amid Declining Vaccine Sales and Profit Drop

GSK reported a 19% drop in pre-tax profit for the third quarter, driven by restructuring charges and falling sales for key shingles and RSV vaccines. Despite beating some financial expectations, the pharmaceutical giant's weaker outlook and upcoming patent losses unsettled investors, causing its shares to slide.